Impact on carer burden when stable patients with schizophrenia transitioned from 1-monthly to 3-monthly paliperidone palmitate

by Rebekka Lencer, Maria Paz Garcia-Portilla, Paul Bergmans, Srihari Gopal, Maju Mathews, Annette Wooller, Katalin Pungor
Published 2021-05-01

Stable patients with schizophrenia switched to paliperidone palmitate 3-monthly formulation in a naturalistic setting: impact of patient age and disease duration on outcomes

by Katalin Pungor, Vasilis P. Bozikas, Robin Emsley, Pierre-Michel Llorca, Srihari Gopal, Maju Mathews, Annette Wooller, Paul Bergmans
Published 2020-12-01

The Patient, Investigator, Nurse, Carer Questionnaire (PINC-Q): a cross-sectional, retrospective, non-interventional study exploring the impact of less frequent medication administ...

by Katalin Pungor, Pedro Sanchez, Sofia Pappa, Jerome Attal, Karolina Leopold, Geertje Steegen, Antonio Vita, Carol Marsella, Caroline Verrijcken, Marjolein Lahaye, Annette Wooller
Published 2021-06-01

Symptomatic and functional outcomes after treatment with paliperidone palmitate 3-month formulation for 52 weeks in patients with clinically stable schizophrenia

by Maria Paz Garcia-Portilla, Pierre-Michel Llorca, Giuseppe Maina, Vasilis P. Bozikas, Halise Devrimci-Ozguven, Sung-Wan Kim, Paul Bergmans, Irina Usankova, Katalin Pungor
Published 2020-05-01